Beiersdorf AG is pursuing a “bold” repositioning of its business in China, shifting its focus from less strategic and price-sensitive personal care categories to premium products, including a rollout of its successful Thiamidol skin care in the country in 2026, according to CEO Vincent Warnery.
“This follows the official approval of our patented ingredient Thiamidol in China last year – a major milestone for Beiersdorf. It is only the second hyperpigmentation ingredient to receive such...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?